HB 1881 creates a new state review and approval process for certain “material change transactions” in Washington’s health care marketplace, including mergers, acquisitions, and contracting affiliations involving hospitals, hospital systems, provider organizations, carriers, and some out-of-state entities doing substantial business in Washington. The bill requires advance written notice to the Washington State Health Care Authority and the Attorney General, establishes definitions for key terms, and sets out timelines for preliminary review, comprehensive review, public hearings, and final decisions. It also authorizes the Attorney General to approve a transaction, approve it with conditions or modifications, or disapprove it, and it provides for appeals to superior court.
The bill is designed to ensure that health care consolidation does not reduce competition, raise prices, or diminish access to affordable, quality care. In addition to antitrust review, it requires an access, affordability, quality, and equity assessment that examines impacts on patient access, health disparities, staffing, charity care, community benefit programs, language access, disability access, and care for medically underserved populations. The bill also imposes post-closing monitoring for at least five years, annual reporting, public comment opportunities, and civil penalties for noncompliance. It applies to pending transactions only if no letter of intent was signed before the effective date, and it is titled the “Keep Our Care Act.”
The bill’s impact on state law is substantial: it adds a new chapter to Washington law governing health care transactions and expands the procedural and substantive review authority of the Attorney General and Health Care Authority. It supplements existing antitrust and consumer protection laws by requiring notice for transactions that may not meet federal Hart-Scott-Rodino thresholds, authorizing public hearings and information collection, and allowing the state to block or condition transactions that would materially harm access to care. It also creates confidentiality rules, fee authority, monitoring powers, and enforcement tools including injunctions, restitution, disgorgement, and civil penalties.
The general sentiment reflected in the bill text is strongly supportive of state oversight and skeptical of health care consolidation. The findings section emphasizes the importance of accessible and affordable care, the harms of anticompetitive mergers, and the need to protect rural and marginalized communities, reproductive health care, gender-affirming care, and end-of-life services. Because there are no committee transcripts or recorded votes provided, there is no additional evidence of debate or bipartisan support/opposition beyond the bill’s own policy framing.
The main points of contention built into the bill are the breadth of state review, the amount of information required from parties, the Attorney General’s authority to impose conditions or reject transactions, and the potential burden on providers and health systems. The bill also anticipates disputes over confidentiality, emergency expedited review, and whether a transaction can be conditioned on maintaining staffing, charity care, service levels, and access in underserved areas. In short, supporters would likely view the bill as a consumer- and patient-protection measure, while opponents may see it as a significant regulatory barrier to health care restructuring and investment.
HB 1881 would add a new Washington statutory framework governing notice, review, approval, conditioning, disapproval, and post-closing monitoring of material health care transactions. It expands the roles of the Attorney General and Health Care Authority, creates new reporting and public-hearing requirements, authorizes civil penalties and injunctive relief, and applies to a broad range of health care entities and certain out-of-state transactions affecting Washington patients. The bill supplements existing antitrust and consumer protection law without replacing it, and it expressly preserves other state and federal enforcement authority.
The bill is framed in strongly pro-regulation, pro-access terms, with repeated findings that health care consolidation can harm competition, affordability, equity, and access to care. The text signals support for protecting underserved communities, rural areas, reproductive health care, and gender-affirming care, and it emphasizes public oversight and transparency. No committee testimony or votes were provided, so there is no recorded legislative debate to indicate organized support or opposition beyond the bill’s own policy stance.
Likely points of contention include the scope of transactions covered, the volume of required disclosures, the Attorney General’s power to impose conditions or block deals, and the five-year monitoring and reporting obligations. Health systems, hospitals, and provider organizations may object to the administrative burden, delay, and uncertainty, while supporters are likely to argue that these tools are necessary to prevent price increases, service reductions, and loss of access in underserved communities. Confidentiality of business information, emergency expedited review, and the enforceability of access and staffing commitments are also likely areas of dispute.